ESR1 Mutations Affect Anti-proliferative Responses to Tamoxifen through Enhanced Cross-Talk with IGF Signaling

It is now generally accepted that estrogen receptor (ESR1) mutations occur frequently in metastatic breast cancers, however we do not yet know how to best treat these patients. We have modeled the three most frequent hormone binding ESR1 (HBD-ESR1) mutations (Y537N, Y537S, and D538G) using stable le...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Gelsomino, Luca, Gu, Guowei, Rechoum, Yassine, Beyer, Amanda R, Pejerrey, Sasha M, Tsimelzon, Anna, Wang, Tao, Huffman, Kenneth, Ludlow, Andrew, Ando’, Sebastiano, Fuqua, Suzanne AW
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5510243/
https://ncbi.nlm.nih.gov/pubmed/27178332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3829-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados